Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
42.3M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
43.4M
-
Shares change
-
+2.83M
-
Total reported value, excl. options
-
$1.43B
-
Value change
-
+$102M
-
Put/Call ratio
-
0.01
-
Number of buys
-
94
-
Number of sells
-
-68
-
Price
-
$32.89
Significant Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) as of Q3 2024
196 filings reported holding TARS - Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.4M shares
.
Largest 10 shareholders include BlackRock, Inc. (3.76M shares), RTW INVESTMENTS, LP (3.41M shares), Paradigm Biocapital Advisors LP (2.44M shares), TANG CAPITAL MANAGEMENT LLC (2.25M shares), MORGAN STANLEY (2.21M shares), COWEN AND COMPANY, LLC (2.2M shares), JENNISON ASSOCIATES LLC (2.18M shares), VANGUARD GROUP INC (2.1M shares), Frazier Life Sciences Management, L.P. (1.59M shares), and PERCEPTIVE ADVISORS LLC (1.3M shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.